|
|
|
|
http://www.fda.gov/cder/orange/appendix_a.txt
4, ACETAMINOPHEN TYLENOL W/ CODEINE, ACETAMINOPHEN TYLENOL, ACETAMINOPHEN (OTC) TYLOX, ACETAMINOPHEN TYLOX-325, ACETAMINOPHEN TYMTRAN, CERULETIDE DIETHYLAMINE TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE TZ-3, TIOCONAZOLE (OTC) ** U ** U-CORT, HYDROCORTISONE ACETATE U-GENCIN, GENTAMICIN SULFATE UCEPHAN, SODIUM BENZOATE ULO, CHLOPHEDIANOL HYDROCHLORIDE ULTANE, SEVOFLURANE ULTIVA...
|
|
|
Prescription and OTC Drug Product List 6/2002
ACTHAR GEL -D- BC + QUESTCOR PHARMS 40 UNITS/ML N08372 006 JUL DISC -A- @ 40 UNITS/ML N08372 006 JUL DISC DIATRIZOATE SODIUM SOLUTION; ORAL, RECTAL HYPAQUE -D- AMERSHAM HLTH 40% N11386 003 JUL DISC -A- @ 40% N11386 003 JUL DISC DICLOFENAC SODIUM GEL; TOPICAL SOLARAZE -A- + BIOGLAN PHARMA 3% N21005 001 OCT 16, 2000 JUL CAHN -D- + BIOGLAN PHARMA PLC 3% N21005 001 OCT 16, 2000 JUL CAHN...
|
|
|
Excessive Hairiness: Hair Disorders: Merck Manual Home Edition
Search Recent Searches Index Sections A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Accidents and Injuries Blood Disorders Bone, Joint, and Muscle Disorders Brain, Spinal Cord, and Nerve Disorders Cancer Children's Health Issues Digestive Disorders Disorders of Nutrition and Metabolism Drugs Ear, Nose, and Throat Disorders Eye Disorders Fundamentals Heart and Blood Vessel...
|
|
|
Symptoms: Symptoms and Diagnosis of Gynecologic Disorders: Merck Manual Home Edition
Search Recent Searches Index Sections A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Accidents and Injuries Blood Disorders Bone, Joint, and Muscle Disorders Brain, Spinal Cord, and Nerve Disorders Cancer Children's Health Issues Digestive Disorders Disorders of Nutrition and Metabolism Drugs Ear, Nose, and Throat Disorders Eye Disorders Fundamentals Heart and Blood Vessel...
|
|
|
Vaniqa J4699
DESCRIPTION VANIQA TM is a cream containing 13.9% (139 mg/ g) of anhydrous eflornithine hydrochloride as eflornithine hydrochloride monohydrate( 150 mg/ g)
The apparent steady- state plasma t1/ 2 of eflornithine was approximately 8 hours
Women with facial conditions such as severe inflammatory acne, women who were pregnant, and nursing mothers were excluded from the studies
author: Ray
duplicates:
http://www.womenfirst.com/pdf/vaniqa.pdf
|
|
|
Vaniqa J4699 page 2
author: Ray
duplicates:
http://www.womenfirst.com/pdf/vaniqa.pdf
|
|
|
http://www.fda.gov/cder/foi/label/2000/21145lbl.pdf
Eflornithine did not elicit mutagenic effects in an Ames reverse- mutation assay or clastogenicity in primary human lymphocytes, with and without metabolic activation
Vehicle- Controlled Studies Vehicle- Controlled and Open- Label Studies Adverse Event Term VANIQA (n= 393) Vehicle (n= 201) VANIQA (n= 1373) Acne 21.3 21.4 10.8 Pseudofolliculitis Barbae 16.3 15.4 4...
|
|
|
http://www.fda.gov/cder/foi/label/2000/21145lbl.pdf page 4
|
|
|
Database E
E - investigational drugs, therapies and vaccines # - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z From this page you may order documents with information covering investigational products To purchase documents on-line click on- link attached to selected document!- The fee is $15 per document Documents are delivered by e-mail...
|
|
|
Introduction - Modular EPARs S-Z
Authorised Medicinal Products for Human Use - Download a PDF copy of the List of Products. S Sifrol INN:Pramipexole (Rev. 4) Simulect INN:Basiliximab (Rev. 2) Sonata INN:Zaleplon (Rev. 2) SonoVue INN:Sulphur ...
|
